Bristol-Myers Squibb, a United States-based pharmaceutical company, has revealed results from a Phase three randomised, double blind study
of Yervoy (ipilimumab) 10 mg/kg (n=475), it was reported yesterday.
The Phase III double blind study
involved 808 people with HER2-positive mBC, which recurred after prior therapy in the adjuvant or neoadjuvant setting.
Instead of using a retrospective (historical controls) study, they used a prospective, randomized, double blind study
. Such a research design protects against "conscious or unconscious bias on the part of investigators," the researchers say.